Lonza is further reshaping the ADC landscape by introducing new Drug Product capabilities that enable end-to-end development and manufacturing of cytotoxic bioconjugates.

Through the innovative Ibex® Design solution, Lonza can shorten your CMC path to IND to just 15 months.

  • Fully integrated end-to-end solutions
  • Drug product delivery in minimum 15 months
  • Possible to get tox drug substance in 8 months
  • Submission-ready CMC data for your IND/IMPD

Preview this webinar

Get immediate access to the full webinar by filling out the form on this page.

Full webinar highlights

Register for full webinar access to learn about how Lonza facilitates successful early phase development and IND submission through:

  • Holistic development strategy with the end point in mind​
  • Leading bioconjugate expertise
  • Integrated supply chain all under one roof
  • Phase appropriate quality requirements defined​
  • A robust process design backed up by decades of experience
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center